XenoMouse Animals Sample Clauses

XenoMouse Animals. On the terms and conditions of this Agreement, ABX will provide free of charge to GNE such types, strains and quantities, as GNE reasonably requests, of sterilized male XenoMouse Animals of the highest quality reasonably available for immunization with Specified Antigens; provided however, that ABX's obligation to provide such XenoMouse Animals free of charge shall be limited to providing GNE with up to [*] XenoMouse Animals per month and up to a total of [*] XenoMouse Animals per calendar year. GNE shall use such XenoMouse Animals solely for the purposes set forth in this Agreement. Notwithstanding anything to the contrary in this Agreement, unless ABX otherwise agrees in writing, ABX shall not be required to provide GNE with more than (a) [*] XenoMouse Animals in any given calendar month, or (b) [*] XenoMouse Animals in any given calendar year, in the aggregate. Subject to availability, ABX will provide to GNE reasonable quantities of XenoMouse Animals requested by GNE hereunder in excess of the number of XenoMouse Animals set forth in clauses (a) and (b) above at a cost to GNE of [*] per XenoMouse Animal.
Sample 1
AutoNDA by SimpleDocs
XenoMouse Animals. (a) Subject to the terms and conditions of this Agreement, JTI and Majority-Owned Affiliates of JTI, solely as needed to practice any rights that may be granted in accordance with Section 2.3.5, shall have the right, but not the obligation, to maintain the [*] JTI shall use such XenoMouse Animals (the "Original Strains"), and any other XenoMouse Animals it acquires pursuant to this Agreement, solely for the purposes set forth in this Agreement in accordance with the terms hereof.
Sample 1
XenoMouse Animals. Subject to the terms and conditions of this Agreement, including those set forth in Section 2.2 below, on or before the Effective Date, ABX has provided to MBio, solely for use in creating Antibodies to the Antigen for use in the Research Field, XenoMouse Animals pursuant to the RCA.
Sample 1

Related to XenoMouse Animals

  • Animals Except for guide, signal or service dogs in use by a blind, deaf or physically handicapped person or a watch dog used by the Tenant, no animals shall be allowed, even temporarily, anywhere in or on the Property without the Landlord’s prior written consent, which consent may be withheld, conditioned or delayed at the Landlord’s discretion.

  • Know-How The term “

  • Licensed Technology The term "Licensed Technology" shall mean the ------------------- Licensed Patents, plus all improvements thereto developed by Licensor, and all related data, know-how and technology.

  • Clinical Data The descriptions of the results of any studies and tests conducted by or on behalf of, or sponsored by, the Company or its subsidiaries, or in which the Company has participated, that are described in the Disclosure Package and the Prospectus, or the results of which are referred to in the Disclosure Package and the Prospectus do not contain any misstatement of material fact or omit to state a material fact necessary to make such statements not misleading. The Company has no knowledge of any studies or tests not described in the Disclosure Package and the Prospectus the results of which reasonably call into question in any material respect the results of the studies, tests and trials described in the Disclosure Package or Prospectus.

  • Clinical Data and Regulatory Compliance The preclinical tests and clinical trials conducted by the Company, and to the knowledge of the Company, the preclinical tests and clinical trials conducted on behalf of or sponsored by the Company, that are described in, or the results of which are referred to in, the Registration Statement, the Time of Sale Prospectus or the Prospectus were and, if still pending, are being conducted in all material respects in accordance with the protocols, procedures and controls designed and approved for such studies and with standard medical and scientific research procedures and all applicable laws and regulations, including, without limitation, 21 C.F.R. Parts 50, 54, 56, 58, and 312; each description of the results of such studies is accurate and complete in all material respects and fairly presents the data derived from such studies, and the Company and its subsidiaries have no knowledge of any other studies the results of which are inconsistent with, or otherwise call into question, the results described or referred to in the Registration Statement, the Time of Sale Prospectuses or the Prospectus; the Company and its subsidiaries have made all such filings and obtained all such Permits as may be required by the Food and Drug Administration of the U.S. Department of Health and Human Services or any committee thereof or from any other U.S. or foreign government or drug or medical device regulatory agency, or health care facility Institutional Review Board (collectively, the “Regulatory Agencies”) for the operation of the Company’s business as currently conducted, except as would not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect; neither the Company nor any of its subsidiaries has received any notice of, or correspondence from, any Regulatory Agency requiring the termination, suspension or modification of any clinical trials that are described or referred to in the Registration Statement, the Time of Sale Prospectus or the Prospectus; and the Company and its subsidiaries have each operated and currently are in compliance in all material respects with all applicable rules and regulations of the Regulatory Agencies except as would not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect.

  • Third Party Technology The assignment of any applicable license agreements with respect to Third Party Technology are set forth in the General Assignment and Assumption Agreement.

  • Licensed Products Lessee will obtain no title to Licensed Products which will at all times remain the property of the owner of the Licensed Products. A license from the owner may be required and it is Lessee's responsibility to obtain any required license before the use of the Licensed Products. Lessee agrees to treat the Licensed Products as confidential information of the owner, to observe all copyright restrictions, and not to reproduce or sell the Licensed Products.

  • Background Technology List here prior contracts to assign Inventions that are now in existence between any other person or entity and you. [ ] List here previous Inventions which you desire to have specifically excluded from the operation of this Agreement. Continue on reverse side if necessary.

  • Commercialization Intrexon shall have the right to develop and Commercialize the Reverted Products itself or with one or more Third Parties, and shall have the right, without obligation to Fibrocell, to take any such actions in connection with such activities as Intrexon (or its designee), at its discretion, deems appropriate.

  • Research Neither the Investor nor any Affiliate of the Investor shall have, in the prior thirty (30) days, published or distributed any research report (as such term is defined in Rule 500 of Regulation AC) concerning the Company.

Time is Money Join Law Insider Premium to draft better contracts faster.